217 related articles for article (PubMed ID: 2570730)
21. Determining the optimal dosage regimen for H2-receptor antagonist therapy--a dose validation approach.
Young MD; Frank WO; Dickson BD; Peace KP; Braverman A; Mounce W
Aliment Pharmacol Ther; 1989 Feb; 3(1):47-57. PubMed ID: 2577482
[TBL] [Abstract][Full Text] [Related]
22. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Baglioni A; Barbara L; Bianchi-Porro G; Blasi A; Canelli B; Cheli R; Dal Monte R; Dammann HG; Francavilla A; Hentschel E
Z Gastroenterol; 1985 Dec; 23(12):665-9. PubMed ID: 2868581
[TBL] [Abstract][Full Text] [Related]
23. A multicenter, randomized, double-blind study comparing once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of active duodenal ulcer.
Alcalá Santaella R; Guardia J; Pajares J; Pique J; Pita L; Alvárez E; Castellanos P; Guarner L; Ortiz J; Pesquera R
Hepatogastroenterology; 1989 Jun; 36(3):168-71. PubMed ID: 2666293
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine.
Savarino V; Mela GS; Scalabrini P; Fera G; Zentilin P; Sumberaz A; Celle G
Eur J Clin Pharmacol; 1988; 35(2):203-7. PubMed ID: 3191940
[TBL] [Abstract][Full Text] [Related]
25. The 24-hour acid suppression profile of nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
[TBL] [Abstract][Full Text] [Related]
26. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
[TBL] [Abstract][Full Text] [Related]
27. [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
Z Gastroenterol; 1985 Feb; 23(2):47-51. PubMed ID: 2865859
[TBL] [Abstract][Full Text] [Related]
28. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
Thomson AB
Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583
[TBL] [Abstract][Full Text] [Related]
29. A multicenter, randomized, double-blind study comparing a daily bedtime administration of famotidine and ranitidine in short-term treatment of active duodenal ulcer.
Alcalá-Santaella R; Guardia J; Pajares J; Piqué J; Pita L; Alvárez E; Castellanos P; Guarner L; Ortiz J; Pesquera R
Digestion; 1989; 42(2):79-85. PubMed ID: 2670647
[TBL] [Abstract][Full Text] [Related]
30. Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.
Savarino V; Mela GS; Zentilin P; Bonifacino G; Moretti M; Valle F; Celle G
Dig Dis Sci; 1989 Jul; 34(7):1043-6. PubMed ID: 2568246
[TBL] [Abstract][Full Text] [Related]
31. Famotidine in the USA: a review of efficacy studies.
Gitnick G
J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
[TBL] [Abstract][Full Text] [Related]
32. Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group.
Cloud ML; Enas N; Offen WW
Clin Pharmacol Ther; 1992 Sep; 52(3):307-13. PubMed ID: 1526089
[TBL] [Abstract][Full Text] [Related]
33. [Effect of an H+, K+-ATPase inhibitor, omeprazole (OPZ), on gastric acid secretion and gastric or duodenal lesion. Comparison with an H2-receptor antagonist, famotidine (FMD)].
Haga K; Asano K; Osuga K; Maruyama Y
Nihon Yakurigaku Zasshi; 1988 Jul; 92(1):39-47. PubMed ID: 2906028
[TBL] [Abstract][Full Text] [Related]
34. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion.
Ryan JR; Vargas R; McMahon FG; Chremos AN
Am J Med; 1986 Oct; 81(4B):60-4. PubMed ID: 2877576
[TBL] [Abstract][Full Text] [Related]
35. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
36. Double-blind comparison of the safety and efficacy of famotidine with ranitidine in patients with endoscopically diagnosed peptic ulcer.
Sawant PD; Nanivadekar SA; Patel HD; Shroff CP; Oke VG; Jha RJ; Bowalekar SK; Navani SR; Raghu CN
J Assoc Physicians India; 1990 Sep; 38 Suppl 1():723-6. PubMed ID: 2092029
[TBL] [Abstract][Full Text] [Related]
37. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring.
Savarino V; Picciotto A; Magnolia MR; Scalabrini P; Mela GS; Celle G
J Clin Pharmacol; 1987 Oct; 27(10):790-3. PubMed ID: 2892864
[TBL] [Abstract][Full Text] [Related]
38. [Effects of IT-066, a new histamine H2-receptor antagonist, on gastric acid secretion and experimental gastric ulcers in rats and dogs].
Okabe S; Nishida T; Igata H; Takagi K
Nihon Yakurigaku Zasshi; 1990 May; 95(5):247-56. PubMed ID: 1972370
[TBL] [Abstract][Full Text] [Related]
39. Comparison of famotidine 40 mg with ranitidine 300 mg at night in short-term duodenal ulcer healing. A South African multicentre study.
Marks IN; Wright JP
S Afr Med J; 1987 Jul; 72(1):18-20. PubMed ID: 2885928
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Murakami K; Okimoto T; Kodama M; Tanahashi J; Mizukami K; Shuto M; Abe H; Arita T; Fujioka T
Scand J Gastroenterol; 2011 Mar; 46(3):287-92. PubMed ID: 21073372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
